New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
− Primary endpoint defined as the proportion of patients who achieved confirmed CMV viremia clearance at the end of Study Week 8 OSAKA, Japan–(BUSINESS WIRE)–...